IL148357A0 - Pharmaceutical compositions containing a benzamide derivative - Google Patents

Pharmaceutical compositions containing a benzamide derivative

Info

Publication number
IL148357A0
IL148357A0 IL14835700A IL14835700A IL148357A0 IL 148357 A0 IL148357 A0 IL 148357A0 IL 14835700 A IL14835700 A IL 14835700A IL 14835700 A IL14835700 A IL 14835700A IL 148357 A0 IL148357 A0 IL 148357A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
benzamide derivative
benzamide
derivative
Prior art date
Application number
IL14835700A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL148357A0 publication Critical patent/IL148357A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14835700A 1999-08-30 2000-08-29 Pharmaceutical compositions containing a benzamide derivative IL148357A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24244499A JP2001081031A (ja) 1999-08-30 1999-08-30 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
PCT/EP2000/008421 WO2001016106A1 (en) 1999-08-30 2000-08-29 Benzamide formulation with histone deacetylase inhibitor activity

Publications (1)

Publication Number Publication Date
IL148357A0 true IL148357A0 (en) 2002-09-12

Family

ID=17089193

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14835700A IL148357A0 (en) 1999-08-30 2000-08-29 Pharmaceutical compositions containing a benzamide derivative
IL148357A IL148357A (en) 1999-08-30 2002-02-25 Pharmaceutical preparations containing derivatives of benzamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148357A IL148357A (en) 1999-08-30 2002-02-25 Pharmaceutical preparations containing derivatives of benzamide

Country Status (32)

Country Link
US (1) US6638530B1 (bg)
EP (1) EP1208086B1 (bg)
JP (2) JP2001081031A (bg)
KR (1) KR100712640B1 (bg)
CN (1) CN1147472C (bg)
AR (1) AR025434A1 (bg)
AT (1) ATE318258T1 (bg)
AU (1) AU773617B2 (bg)
BG (1) BG65544B1 (bg)
BR (1) BR0013648A (bg)
CA (1) CA2382886C (bg)
CZ (1) CZ301737B6 (bg)
DE (1) DE60026144T2 (bg)
DK (1) DK1208086T3 (bg)
EE (1) EE05063B1 (bg)
ES (1) ES2259289T3 (bg)
HK (1) HK1046277B (bg)
HR (1) HRP20020182B1 (bg)
HU (1) HUP0203330A3 (bg)
IL (2) IL148357A0 (bg)
MX (1) MXPA02002090A (bg)
NO (1) NO322532B1 (bg)
NZ (1) NZ517520A (bg)
PL (1) PL201274B1 (bg)
PT (1) PT1208086E (bg)
RU (1) RU2260428C2 (bg)
SI (1) SI1208086T1 (bg)
SK (1) SK287252B6 (bg)
TW (1) TWI268778B (bg)
UA (1) UA72541C2 (bg)
WO (1) WO2001016106A1 (bg)
ZA (1) ZA200201424B (bg)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
EP1374855A1 (en) * 2001-03-30 2004-01-02 Takeda Chemical Industries, Ltd. Medicinal solutions
AU2002327627B2 (en) * 2001-09-14 2006-09-14 Methylgene Inc. Inhibitors of histone deacetylase
AU2006252047B2 (en) * 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
WO2003032921A2 (en) 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
JPWO2003070691A1 (ja) * 2002-02-21 2005-06-09 財団法人大阪産業振興機構 Ｎ−ヒドロキシカルボキサミド誘導体
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
ES2532607T3 (es) 2002-03-04 2015-03-30 Merck Hdac Research, Llc Métodos de inducción de la diferenciación terminal
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
WO2003075856A2 (en) 2002-03-07 2003-09-18 University Of Delaware Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
DE10233412A1 (de) * 2002-07-23 2004-02-12 4Sc Ag Neue Verbindungen als Histondeacetylase-Inhibitoren
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0226855D0 (en) * 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
US7244751B2 (en) * 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
CN100455564C (zh) * 2003-09-12 2009-01-28 深圳微芯生物科技有限责任公司 组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
CN101445469B (zh) * 2003-09-24 2013-02-13 梅特希尔基因公司 组蛋白脱乙酰基酶抑制剂
WO2005030705A1 (en) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
DK1696898T3 (en) 2003-12-02 2016-02-22 Univ Ohio State Res Found ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS
EP1697538A1 (en) * 2003-12-18 2006-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Method for identifying histone deacetylase inhibitors
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
US20100152188A1 (en) * 2005-08-05 2010-06-17 Akella Satya Surya Visweswara Srinivas Novel Heterocyclic Compounds
MX2008012678A (es) * 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
US8598168B2 (en) 2006-04-07 2013-12-03 Methylgene Inc. Inhibitors of histone deacetylase
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2008123395A1 (ja) 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤
CA2706750A1 (en) * 2007-11-27 2009-06-04 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
KR20110007242A (ko) * 2008-05-07 2011-01-21 메리온 리서치 Ⅲ 리미티드 펩티드 조성물 및 그의 제조 방법
WO2009140164A1 (en) * 2008-05-16 2009-11-19 Chipscreen Biosciences Ltd. 6-aminonicotinamide derivatives as potent and selective histone deacetylase inhibitors
US8623853B2 (en) 2008-07-23 2014-01-07 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the NUT gene
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
CN103172540B (zh) * 2013-03-18 2015-07-01 潍坊博创国际生物医药研究院 苯甘氨酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
ES2975708T3 (es) 2015-01-29 2024-07-12 Novo Nordisk As Comprimidos que comprenden agonista del GLP-1 y recubrimiento entérico
KR102688052B1 (ko) 2015-07-02 2024-07-25 아세르타 파마. 비.브이. (S)-4-(8-아미노-3-(1-(부트-2-이노일)피롤리딘-2-일)이미다조[1,5-a]피라진-1-일)-N-(피리딘-2-일)벤즈아마이드의 고체 형태 및 제제
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20190224146A1 (en) * 2016-07-08 2019-07-25 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing lysosomal storage diseases and other monogenetic metabolic diseases
WO2018222572A1 (en) * 2017-06-01 2018-12-06 Warner Babcock Institute For Green Chemistry, Llc Non-covalent derivatives and methods of treatment
US20180353446A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
JP7183403B2 (ja) 2019-04-25 2022-12-05 富士製薬工業株式会社 医薬製剤およびその製造方法
CN112294810B (zh) * 2019-07-29 2024-03-01 深圳微芯生物科技股份有限公司 含有西达本胺和表面活性剂的药物组合物
JPWO2022091442A1 (bg) 2020-10-28 2022-05-05

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737631T3 (de) * 1996-08-12 2011-08-18 Mitsubishi Tanabe Pharma Corp. MEDIKAMENTE ENTHALTEND Rho-KINASE INHIBITOREN
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP4405602B2 (ja) * 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
JP2000256194A (ja) * 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤

Also Published As

Publication number Publication date
HUP0203330A3 (en) 2004-03-01
DK1208086T3 (da) 2006-06-19
AU6841600A (en) 2001-03-26
JP2001081031A (ja) 2001-03-27
CN1147472C (zh) 2004-04-28
HUP0203330A2 (hu) 2003-02-28
SK287252B6 (sk) 2010-04-07
MXPA02002090A (es) 2003-08-20
HRP20020182B1 (en) 2007-08-31
RU2260428C2 (ru) 2005-09-20
ZA200201424B (en) 2002-11-27
NO20020952D0 (no) 2002-02-27
CA2382886C (en) 2009-06-09
WO2001016106A1 (en) 2001-03-08
SK2612002A3 (en) 2002-09-10
CZ2002724A3 (cs) 2002-07-17
BG65544B1 (bg) 2008-11-28
HK1046277A1 (en) 2003-01-03
CZ301737B6 (cs) 2010-06-09
KR20020023424A (ko) 2002-03-28
IL148357A (en) 2006-12-10
ATE318258T1 (de) 2006-03-15
KR100712640B1 (ko) 2007-05-02
EE05063B1 (et) 2008-08-15
HK1046277B (zh) 2004-11-26
ES2259289T3 (es) 2006-10-01
DE60026144T2 (de) 2006-11-16
TWI268778B (en) 2006-12-21
NO20020952L (no) 2002-03-20
US6638530B1 (en) 2003-10-28
PL201274B1 (pl) 2009-03-31
NO322532B1 (no) 2006-10-23
EP1208086B1 (en) 2006-02-22
NZ517520A (en) 2003-05-30
JP2003508386A (ja) 2003-03-04
CN1371366A (zh) 2002-09-25
BR0013648A (pt) 2002-05-07
EE200200097A (et) 2003-04-15
CA2382886A1 (en) 2001-03-08
SI1208086T1 (sl) 2006-08-31
DE60026144D1 (de) 2006-04-27
UA72541C2 (en) 2005-03-15
HRP20020182A2 (en) 2004-02-29
EP1208086A1 (en) 2002-05-29
AR025434A1 (es) 2002-11-27
BG106439A (bg) 2002-11-29
AU773617B2 (en) 2004-05-27
PT1208086E (pt) 2006-07-31
PL353063A1 (en) 2003-10-06

Similar Documents

Publication Publication Date Title
IL148357A0 (en) Pharmaceutical compositions containing a benzamide derivative
IL149138A0 (en) Pharmaceutical compositions containing metformin
HUP0202513A3 (en) Betha-carboline pharmaceutical compositions
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
IL145177A0 (en) A pharmaceutical composition containing xenon
IL147778A0 (en) Pharmaceutical compositions containing cyclobenzaprine
PL351387A1 (en) Pharmaceutical composition
HK1044476A1 (en) Medicinal compositions
GB9923436D0 (en) Pharmaceutical compositions
EP1166786A4 (en) MEDICAL COMPOSITIONS
IL148169A0 (en) Pharmaceutical compositions containing a benzamide derivative
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
GB9904163D0 (en) Pharmaceutical compositions
IL145632A0 (en) Pharmaceutical compounds
GB9916434D0 (en) Pharmaceutical compounds
GB9911017D0 (en) Pharmaceutical compositions
IL148725A0 (en) Aqueous pharmaceutical compositions containing circlesonide
GB9914255D0 (en) Pharmaceutical compounds
GB9903784D0 (en) Pharmaceutical compounds
GB9904911D0 (en) Pharmaceutical compositions
IL122891A0 (en) Pharmaceutical compositions comprising a thiocarbamate
IL149470A0 (en) Pharmaceutical compositions containing carboxamidoadenosine derivatives
GB2373499B (en) Pharmaceutical compounds
IL130325A0 (en) Pharmaceutical compositions comprising allicin

Legal Events

Date Code Title Description
KB Patent renewed
FF Patent granted